The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2025 | Integrated treatment approaches for limited stage SCLC
Bjorn Henning Gronberg, MD, PhD, Norwegian University of Science and Technology, Trondheim, Norway, comments on integrating maintenance immunotherapy into the treatment paradigm for patients with limited stage small cell lung cancer (SCLC). The randomized Phase II trial (NCT03540420) investigating whether atezolizumab following chemoradiotherapy aids survival has shown positive results, with a tolerable treatment approach prolonging median overall survival. Long term data is still needed to confirm findings. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Based on the very positive results of the ADRIATIC trial that was presented at last year’s ASCO meeting, I think it’s quite clear that this is the new standard of care. The prolongation in median overall survival was meaningful, but what we need is more data on the long-term survival. I think our study results further add to the data that this treatment approach is tolerable for patients...
Based on the very positive results of the ADRIATIC trial that was presented at last year’s ASCO meeting, I think it’s quite clear that this is the new standard of care. The prolongation in median overall survival was meaningful, but what we need is more data on the long-term survival. I think our study results further add to the data that this treatment approach is tolerable for patients. After all, 35% of our patients completed one year of atezolizumab immunotherapy, and we didn’t see any new safety signals.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Employment – Lilly (I)
Stock and Other Ownership Interests – Lilly (I)
Honoraria – AstraZeneca; BMS Norway; Gilead Sciences; Janssen; Lilly; MSD; Pfizer
Consulting or Advisory Role – Accord Healthcare; AstraZeneca; Janssen; MSD
Research Funding – AstraZeneca (Inst); Roche (Inst)
